NASDAQ:KLDO - Kaleido Biosciences Stock Price, Forecast & News

Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."

Kaleido Biosciences Inc (NASDAQ:KLDO) issued its earnings results on Wednesday, October, 30th. The company reported ($0.74) EPS for the quarter, topping the Zacks' consensus estimate of ($0.89) by $0.15. View Kaleido Biosciences' Earnings History.

Kaleido Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, January 29th 2020. View Earnings Estimates for Kaleido Biosciences.

5 equities research analysts have issued 12-month price objectives for Kaleido Biosciences' shares. Their forecasts range from $15.00 to $20.00. On average, they expect Kaleido Biosciences' share price to reach $17.70 in the next twelve months. This suggests a possible upside of 251.9% from the stock's current price. View Analyst Price Targets for Kaleido Biosciences.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kaleido Biosciences.

Headlines about KLDO stock have trended very negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kaleido Biosciences earned a media sentiment score of -3.6 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Kaleido Biosciences.

Kaleido Biosciences saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,820,000 shares, an increase of 20.5% from the December 15th total of 1,510,000 shares. Based on an average daily trading volume, of 123,900 shares, the short-interest ratio is presently 14.7 days. Currently, 20.2% of the shares of the company are short sold. View Kaleido Biosciences' Current Options Chain.

Some companies that are related to Kaleido Biosciences include Advanced Medical Solutions Group (AMS), Prevail Therapeutics (PRVL), Replimune Group (REPL), Medical Developments International (MVP), Crinetics Pharmaceuticals (CRNX), Global Cord Blood (CO), Proteon Therapeutics (PRTO), AxoGen (AXGN), Cerus (CERS), Kura Oncology (KURA), Oxford BioMedica (OXBDF), Oceania Healthcare (OCA), AngioDynamics (ANGO), Morphic (MORF) and Establishment Labs (ESTA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Precision BioSciences (DTIL), Gossamer Bio (GOSS), LogicBio Therapeutics (LOGC), Exxon Mobil (XOM), NVIDIA (NVDA), Pfizer (PFE), Akero Therapeutics (AKRO) and Micron Technology (MU).

(KLDO) raised $101 million in an initial public offering (IPO) on Thursday, February 28th 2019. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Shares of KLDO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KLDO stock can currently be purchased for approximately $5.03.

Kaleido Biosciences has a market capitalization of $151.22 million. Kaleido Biosciences employs 118 workers across the globe.View Additional Information About Kaleido Biosciences.